PT4051710T - Terapia de combinação anti-tumoral que inclui anticorpo anti-cd19e células t gama delta - Google Patents

Terapia de combinação anti-tumoral que inclui anticorpo anti-cd19e células t gama delta

Info

Publication number
PT4051710T
PT4051710T PT208001214T PT20800121T PT4051710T PT 4051710 T PT4051710 T PT 4051710T PT 208001214 T PT208001214 T PT 208001214T PT 20800121 T PT20800121 T PT 20800121T PT 4051710 T PT4051710 T PT 4051710T
Authority
PT
Portugal
Prior art keywords
cd19e
antibodies
cells
combination therapy
gamma delta
Prior art date
Application number
PT208001214T
Other languages
English (en)
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PT4051710T publication Critical patent/PT4051710T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT208001214T 2019-10-31 2020-10-30 Terapia de combinação anti-tumoral que inclui anticorpo anti-cd19e células t gama delta PT4051710T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31

Publications (1)

Publication Number Publication Date
PT4051710T true PT4051710T (pt) 2026-02-09

Family

ID=68424789

Family Applications (1)

Application Number Title Priority Date Filing Date
PT208001214T PT4051710T (pt) 2019-10-31 2020-10-30 Terapia de combinação anti-tumoral que inclui anticorpo anti-cd19e células t gama delta

Country Status (22)

Country Link
US (1) US20210130461A1 (pt)
EP (2) EP4051710B1 (pt)
JP (2) JP7688025B2 (pt)
KR (1) KR20220116154A (pt)
CN (1) CN115151565A (pt)
AU (1) AU2020372646A1 (pt)
DK (1) DK4051710T3 (pt)
ES (1) ES3062643T3 (pt)
FI (1) FI4051710T3 (pt)
HR (1) HRP20251630T1 (pt)
IL (1) IL292213A (pt)
LT (1) LT4051710T (pt)
MA (1) MA69251B1 (pt)
MX (1) MX2022005033A (pt)
PH (1) PH12022551009A1 (pt)
PL (1) PL4051710T3 (pt)
PT (1) PT4051710T (pt)
RS (1) RS67602B1 (pt)
SI (1) SI4051710T1 (pt)
SM (1) SMT202600082T1 (pt)
TW (1) TWI883067B (pt)
WO (1) WO2021084063A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR102617497B1 (ko) 2022-09-15 2023-12-27 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
JP2017519757A (ja) * 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP4148124A1 (en) 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
SI3475303T1 (sl) 2016-06-27 2021-12-31 Morphosys Ag Formulacija protitelesa proti CD19
EP3532091A2 (en) * 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Also Published As

Publication number Publication date
TW202547555A (zh) 2025-12-16
TWI883067B (zh) 2025-05-11
MA69251B1 (fr) 2025-12-31
US20210130461A1 (en) 2021-05-06
JP2025134705A (ja) 2025-09-17
PL4051710T3 (pl) 2026-04-20
EP4051710A1 (en) 2022-09-07
LT4051710T (lt) 2026-03-10
HRP20251630T1 (hr) 2026-02-13
CN115151565A (zh) 2022-10-04
JP2022554324A (ja) 2022-12-28
IL292213A (en) 2022-06-01
PH12022551009A1 (en) 2023-03-20
ES3062643T3 (en) 2026-04-13
AU2020372646A1 (en) 2022-05-12
WO2021084063A1 (en) 2021-05-06
CA3158984A1 (en) 2021-05-06
DK4051710T3 (da) 2025-12-15
EP4706673A2 (en) 2026-03-11
MX2022005033A (es) 2022-09-09
KR20220116154A (ko) 2022-08-22
EP4051710B1 (en) 2025-11-26
SMT202600082T1 (it) 2026-03-09
JP7688025B2 (ja) 2025-06-03
TW202131949A (zh) 2021-09-01
FI4051710T3 (fi) 2026-01-12
RS67602B1 (sr) 2026-01-30
SI4051710T1 (sl) 2026-01-30

Similar Documents

Publication Publication Date Title
PT4051710T (pt) Terapia de combinação anti-tumoral que inclui anticorpo anti-cd19e células t gama delta
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
EP3749311A4 (en) PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
IL292673A (en) Combined treatment by anti-pvrig antibody and anti-pd-1 antibody formulations
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP3630980A4 (en) CHIMERIC ANTIGEN RECEPTOR CELL PREPARATION AND USES THEREOF
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
MX2019008348A (es) Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA52542A (fr) Thérapie cellulaire adoptive
MX2025010681A (es) Formulaciones transdermicas
SG11202009990UA (en) Modified antibody and radioactive metal-labelled antibody
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
SG11202101875VA (en) Anti-cd3 antibody folate bioconjugates and their uses
IL276008A (en) Antibodies that increase factor h activity and their uses
EP3778234A4 (en) LAMINATE AND PACKAGING WITH USE OF IT
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
EP3755717A4 (en) THERAPEUTIC ANTIBODY AND USES THEREOF
IL291550A (en) Anti-il-27 antibodies and uses thereof
SG11202007471WA (en) Granzyme b directed imaging and therapy
SG11202011170YA (en) Antibodies against lif and dosage forms thereof
EP3938051A4 (en) PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF